Stocks Health care GANX
NASDAQ · Health careGain Therapeutics, Inc. (GANX)
It posted a net loss of $20.1M. At June 30, 2026 it held $13.1M in cash against $343.7K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Gain Therapeutics, Inc.
- Net worth
- Gain Therapeutics, Inc. has a market value (market cap) of $50.2M at the latest share price, and shareholders' equity of $11.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $55.2K (-60.6% year on year), with a net loss of $22.3M.
- Cash flow
- In fiscal 2025 operations used $18.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Gain Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Gain Therapeutics, Inc. does
Gain Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GANX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$20.2M | -$0.61 | n/a |
| 2024 | n/a | -$20.4M | -$0.89 | -$18.9M |
| 2023 | $55.2K | -$22.3M | -$1.71 | -$18.9M |
| 2022 | $140.1K | -$17.6M | -$1.48 | -$14.8M |
| 2021 | $165K | -$13.9M | -$1.37 | -$12.5M |
| 2021 | $28.9K | -$3.6M | -$1.33 | -$3.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Gain Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026Other event 8-K
- September 28, 2026Executive or director change8-KGianluca Fuggetta resigned as Principal Financial Officer, and CEO Gene Mack was appointed interim CFO.
- August 11, 2026
- August 11, 2026
- July 16, 2026Other event 8-K
- June 29, 2026Other event 8-K
- June 25, 2026
- May 26, 2026Other event 8-K
- May 11, 2026
- May 11, 2026
Insider trades
What the people running Gain Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about GANX
What does Gain Therapeutics, Inc. do?
Gain Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as GANX. Its shares trade on NASDAQ under the ticker GANX.
What is Gain Therapeutics, Inc.'s net worth?
Gain Therapeutics, Inc. has a market value (market cap) of $50.2M at the latest share price, and shareholders' equity of $11.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Gain Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $20.1M.
When did Gain Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 1, 2026.
When is Gain Therapeutics, Inc.'s next earnings report?
Gain Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare GANX with
Follow GANX
Get an email when Gain Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Gain Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.